320 results on '"Geller, N."'
Search Results
2. Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3
3. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial
4. Neural modulation for hypertension and heart failure
5. The NHLBI Post-Coronary Artery Bypass Graft Clinical Trial (Post-CABG): angiographic outcomes
6. The effect of frequent hemodialysis on self-reported sleep quality: Frequent Hemodialysis Network Trials
7. Analysis of Chromosome 12 Abnormalities in Male Germ Cell Cancers
8. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity
9. Structural features of the photogeneration mechanism of free charge carriers in element-containing polydisalicylidene azomethine series
10. New germanium- and tin-containing polysalicylideneazomethines derived from tetraamines
11. Photophysical properties of silicon-containing poly[salicylidene azomethine]s
12. Synthesis of new photosensitive silicon-containing poly(salicylideneazomethynes)
13. Synthesis and spectral characteristics of silicon-containing poly(salicylidene azomethines) derived from aromatic di- and tetraamines
14. Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry
15. Correlates of myocardial fibrosis in hypertrophic cardiomyopathy
16. Dipole relaxation, intramolecular mobility, and molecular self-organization in solutions of alternating polymers with phenylazomethine and siloxane fragments
17. Effect of methylene spacer length on the molecular mobility and dipole moment of poly(azomethine esters) with azomethinearomatic groups in the ortho position
18. Directional Synthesis of Hybrid Polymers from 2- and 4-Vinylpyridines
19. Transitioning a randomized controlled trial to a digital registry – experience from the TAILOR-PCI digital follow-up study on onboarding, engagement and geofencing consent rate
20. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry
21. Nephrotic syndrome associated with thrombotic microangiopathy following allogeneic stem cell transplantation for myelodysplastic syndrome – response to Nakamura et al
22. Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation
23. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis
24. Analysis of Chromosome 12 Abnormalities in Male Germ Cell Cancers
25. Randomized Study of Intrahepatic vs Systemic Infusion of Fluorodeoxyuridine in Patients with Liver Metastases from Colorectal Carcinoma (Preliminary Results)
26. Rationale, design, implementation, and baseline characteristics of patients in the dig trial: A large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure
27. Reactions of organometallic compounds with heavy-metal salts: Communication 2. Reaction of ethyllithium with cobalt and titanium halides
28. Statin use and risk of haemorrhagic stroke in a community-based cohort of postmenopausal women: an observational study from the Women's Health Initiative
29. Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?
30. Combined tumor necrosis factor-α (TNF–α) and interleukin-2 (IL-2) blockade in acute steroid refractory graft-versus-host disease (SR-GVHD) following allogeneic hematopoietic stem cell transplantation (HCT)
31. Pre-Transplant T-Cell Lymphopenia Accelerates Early Donor T-Cell and Myeloid Chimerism but Is Not Required for Full Donor Lymphohematopoietic Engraftment or To Prevent Graft Rejection Following Nonmyeloablative Hematopoietic Cell Transplantation (NST).
32. Letter to the Editor
33. Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial.
34. Improved survival in steroid-refractory acute graftversushost disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis
35. Design of complex molecular structures based on 2- and 4-vinylpyridine copolymers
36. Associated risk factors do not prevent the beneficial effect of aggressive cholesterol lowering: post CABG trial
37. Delayed progression of atherosclerosis in coronary bypass grafts is similar in women compared to men following aggressive cholesterol lowering despite more frequent risk factors: post CABG trial
38. After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer.
39. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.
40. Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC.
41. Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease.
42. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection.
43. research paper Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
44. Detecting acute coronary syndrome in the emergency department with cardiac magnetic resonance imaging.
45. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators.
46. The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials.
47. Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy.
48. Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features.
49. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy.
50. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.